Altimmune, Inc.

NasdaqGM:ALT Lagerbericht

Marktkapitalisierung: US$569.8m

Altimmune Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Altimmune hat ein Gesamteigenkapital von $284.0M und eine Gesamtverschuldung von $34.5M, was einen Verschuldungsgrad von 12.2% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $335.6M bzw. $51.6M.

Wichtige Informationen

12.15%

Verhältnis von Schulden zu Eigenkapital

US$34.51m

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$331.54m
EigenkapitalUS$283.99m
GesamtverbindlichkeitenUS$51.64m
GesamtvermögenUS$335.63m

Jüngste Berichte zur Finanzlage

Analyseartikel • Jan 15

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Sep 12

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...
Analyseartikel • Feb 10

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Oct 11

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Jun 27

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Apr 09

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Summary Altimmune has announced it expects to produce topline data from its phase 2 RECLAIM study of pemvidutide in alcohol use disorder. ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway extends into 2028, but further ATM usage or offerings could suppress share price rallies and introduce dilution risk. ALT's RECLAIM study is not without a chance of success, other incretins have shown promise in alcohol use disorder previously. Read the full article on Seeking Alpha
Seeking Alpha • Mar 17

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Summary Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025. Pemvidutide is also being developed for patients with obesity; ALT received clearance from the FDA to run four phase 3 studies for possible eventual marketing approval in targeting these patients. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Summary Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success. Investors should watch for the Phase 2b IMPACT study results in Q2 2025, which could significantly impact Altimmune's stock and future prospects in the MASH market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Summary Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH. Direct peers such as Akero Therapeutics and Madrigal have more advanced clinical trials and are valued at $2 billion and $7 billion, respectively, implying significant upside potential for ALT stock. Comparable catalysts for MASH show that Altimmune, with positive Phase 2 data, could experience a market cap expansion of $475 million, equating to an almost 80% upside. Read the full article on Seeking Alpha
Analyseartikel • Jan 15

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 30

Altimmune Could Find A Partner For Its Phase 3 Exercise

Summary ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Despite competition, the potential for a partnership or buyout remains strong, as Big Pharma continues to show interest in weight loss drugs, and ALT seems cheap compared to its peers. Read the full article on Seeking Alpha
Seeking Alpha • Dec 16

Altimmune 2025: Redefining Obesity And MASH Treatment

Summary Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Summary Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune’s cash runway is estimated to support operations into 1H2026, aligning with expected milestones and anticipated Phase 3 trials. The company plans to expand Pemvidutide’s applications with a new IND for additional indications by year-end, enhancing its market potential. Thus, I am upgrading ALT stock to a “Strong Buy” due to the promising progress of its lead drug candidate, sufficient runway, and several future catalysts. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Regulatory And Clinical Catalysts Ahead For Altimmune

Summary ALT is developing pemvidutide for obesity and liver diseases, with recent MOMENTUM sub-study results showing favorable body composition results. A readout from the Phase 2b trial of pemvidutide in MASH is delayed to Q2'25, although the trial has completed enrollment, making further delays unlikely. ALT has $164.9M in cash but may need additional funding for phase 3 trials; a partnership for phase 3 development in obesity remains a possibility. Read the full article on Seeking Alpha
Seeking Alpha • Oct 02

Consider Buying Potential Takeover Target Altimmune

Summary Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide. Read the full article on Seeking Alpha
Seeking Alpha • Sep 21

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Summary Pemvidutide shows strong potential in obesity and MASH, preserving lean mass while reducing VAT, which could make it a market leader among GLP-1s. Recent Phase II data reveals pemvidutide's lean loss ratio of 21.9%, comparable to diet and exercise, and significant VAT reduction, enhancing its appeal. Despite competition and risks, I am bullish on ALT, upgrading my conviction rating and planning to add to my position below $8.20 per share. Pemvidutide's dual indications for obesity and MASH, along with potential cardiovascular benefits, could drive Altimmune to blockbuster status and significant revenue growth. Read the full article on Seeking Alpha
Analyseartikel • Sep 12

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...
Seeking Alpha • Aug 27

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Summary Weight loss drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune’s pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial's completion. Despite promising data, Altimmune's pemvidutide faces tough competition from established players, making it a risky investment without more differentiating metrics. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Summary Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have demonstrated miraculous weight loss improvements, and will likely dominate a ~$130bn market. Altimmune's latest data shows significant weight loss and lean muscle preservation - the latter may be most significant. If pemvidutide can show it removes less lean muscle fat than competing GLP-1 agonist drugs, it may be on a fast track to approval and a double-digit billion dollar revenue opportunity. It is not quite so simple as it sounds, however - other candidates are yet to fully show their hands, and Altimmune is a minnow compared to the large pharmas crowding this space. Nevertheless, it is an interesting development. Read the full article on Seeking Alpha
Seeking Alpha • May 27

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune. Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 12

Buy Altimmune's Potential Market Disruption With Pemvidutide

Summary Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development. ALT's strategic shift includes partnering discussions to enhance Pemvidutide's development pathway and potential commercialization. Overall I think ALT is a viable investment for investors who are aware of the inherent risks in biotech. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion by 2030. Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025. Altimmune had $198 million in cash as of December 31st of 2023; It will likely have to continue to tap into the ATM agreement or find another way to raise cash to fund its pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Summary Altimmune's stock price has experienced extreme volatility, but jumped by >20% yesterday due to the potential of pemvidutide, a drug candidate for obesity and liver disease. Some analysts believe pemvidutide can have a similar impact as Eli Lilly's tirzepatide and Novo Nordisk's semaglutide on these two indications - both Pharma's share prices have been soaring. Altimmune's previous COVID and anthrax vaccine efforts were unsuccessful, but there is optimism - based on some promising data - that pemvidutide could be different and provide a valuable opportunity. Ultimately, however, with its drug having some problematic side effects and the company struggling for funding, I'm giving Altimmune the thumbs down. There is a data readout in relation to a Hepatitis B therapy due this quarter - a small hedge against pemvidutide struggles - many will disagree, but selling after the recent bull run may be the right option. Read the full article on Seeking Alpha
Seeking Alpha • Feb 12

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon agonist, despite existing competition. Pemvidutide demonstrated dose-dependent weight loss in Phase 2, but high adverse event rates, especially gastrointestinal, led to notable discontinuation. Financially, Altimmune holds a strong current ratio with a 21-month runway despite the need for future capital to sustain operations. Investment Recommendation: Hold ALT stock due to the balance between pemvidutide's potential and its competition, tolerability concerns, and financial health. Read the full article on Seeking Alpha
Analyseartikel • Feb 10

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Summary Altimmune's weight loss drug, Pemvidutide, showed promising results in a phase 2 trial, with a mean weight loss of 15.6% at week 48. The drug also demonstrated better CV risk reduction, lipid changes and tolerability than its competitors, semaglutide and tirzepatide. Altimmune's stock is undervalued compared to the potential market success of a weight loss drug, with potential for significant upside. Read the full article on Seeking Alpha
Analyseartikel • Oct 11

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Jun 27

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ALTDie kurzfristigen Aktiva des Unternehmens ($334.7M) übersteigen seine kurzfristigen Passiva ($11.3M).

Langfristige Verbindlichkeiten: ALTDie kurzfristigen Vermögenswerte des Unternehmens ($334.7M) übersteigen seine langfristigen Verbindlichkeiten ($40.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ALT über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: ALTDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 12.2% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ALT auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: ALT verfügt über eine ausreichende Liquiditätsreserve für 2.8 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 10.8% pro Jahr abnimmt.

Entdecken Sie finanziell stabile Unternehmen

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/27 10:47
Aktienkurs zum Tagesende2026/05/27 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Altimmune, Inc. wird von 19 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Eliana MerleBarclays
William WoodB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.